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IntRoductIon
Iron deficiency (ID) is one of the world’s most prevalent nutrient 
deficiencies [1]. If left untreated, ID can lead to iron deficiency 
anaemia (IDA). Besides oral iron, both ID and IDA can be efficiently 
treated with intravenous (IV) iron. Preparations for IV iron therapy 
that have been available for several years include iron sucrose 
(IS), sodium ferric gluconate, and low and high molecular weight 
iron dextran. However, iron dextrans have been associated with 
dextran-induced anaphylactic reactions (DIARs) [2], and the weaker 
complex, sodium ferric gluconate, contains larger amounts of labile 
iron which, upon administration, may result in saturation of the iron-
binding capacity of transferrin [3].
Ferric carboxymaltose (FCM) is one of the new-generation polynu-
clear iron(III)-hydroxide carbohydrate complexes that was developed 
to overcome the limitations of previous IV iron preparations [4]. 
FCM is a very stable complex with a carboxymaltose shell enabling 
controlled, gradual release of iron within the macrophages of the 
Reticulo-Endothelial System (RES) [4] minimizing the release of 
labile iron into the serum [5]. Therefore, FCM can be administered 
at a single dose of up to 1 g iron in 15 min [6]. Moreover, FCM 
does not contain dextran or dextran derivatives and, thus, cannot 
induce DIARs [4,7], despite the fact that hypersensitivity reactions 
can occur to some extent [6]. Upon IV administration of FCM, iron 
is distributed to the Mononuclear Phagocyte System (MPS) in the 
liver, spleen, and in particular bone marrow, and is utilised effectively 
for red blood cells formation [8]. The efficacy and safety of FCM in 
correcting ID have been demonstrated in a wide range of indications 
in numerous clinical studies across diverse patient populations [6,9]. 
 
Our previous studies in non-anaemic rats have shown that FCM 
has a lower potential to induce oxidative/nitrosative stress and 
inflammation compared to sodium ferric gluconate and dextran-
based IV iron preparations, such as iron dextrans, ferumoxytol, and 
iron isomaltoside 1000 [10-12].
Because FCM is a polynuclear iron-carbohydrate complex, more 
specifically a nanosized colloidal intravenous iron-based preparation, 
FCM can be included in the class of non-biological complex drugs 
(NBCDs) [13]. Due to their complex structure, NBCDs cannot be fully 
characterised by physico-chemical analyses and their therapeutic 
performance is largely defined by the manufacturing process [14]. 
As a consequence, assessment of follow-on products (or better 
‘similar products’) developed with reference to such a NBCD 
should include comparative nonclinical and/or clinical studies that 
evaluate pharmacokinetics and pharmacodynamics [15]. With our 
non-anaemic rat model, we could distinguish between iron sucrose 
originator (IS, Venofer®, a model compound of the NBCD class) 
and several iron sucrose similars (ISSs) [16,17]. In India, a follow-on 
product of FCM, referred to as ferric carboxymaltose similar (FCMS 
is available. In this study, we assessed the potential of this FCMS 
to induce oxidative/nitrosative stress and inflammation in the non-
clinical model and compared the results with those of iron sucrose, 
the established standard in this model.
MAtERIALs And MEtHods
Molecular weight distribution: Molecular weight distribution 
was measured by gel permeation chromatography [18] by the 
Quality Control Laboratory of Vifor (International) Ltd. (St. Gallen, 
Switzerland).
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ABstRAct
Introduction: Ferric carboxymaltose is a next-generation 
polynuclear iron(III)-hydroxide carbohydrate complex for 
intravenous iron therapy belonging to the class of so-called 
non-biological complex drugs. The product characteristics 
and therapeutic performance of non-biological complex drugs 
are largely defined by the manufacturing process. A follow-
on product, termed herein as ferric carboxymaltose similar, 
is available in India. Given that non-biological complex drugs 
may display differences in diverse product properties not 
characterisable by physico-chemical methods alone.
Aim: The  aim  is  to  assess  the effects of this ferric 
carboxymaltose similar in our non-clinical model in non-
anaemic healthy rats.
Materials and Methods: Non-anaemic rats were treated 
with intravenous ferric carboxymaltose similar or iron sucrose 
both at (40 mg iron/kg body weight), or with saline solution 
(control) for four weeks, after which the animals were sacrificed. 
Parameters for tissue iron distribution, oxidative stress, 
nitrosative stress, inflammation and apoptosis were assessed 
by immunohistomorphometry.
Results: Ferric carboxymaltose similar resulted in deranged 
iron distribution versus iron sucrose originator as indicated 
by increased serum iron, transferrin saturation and tissue 
iron(III) deposits as well as decreased ferritin deposits in the 
liver, heart and kidneys versus iron sucrose originator. Ferric 
carboxymaltose similar also increased significantly oxidative/
nitrosative stress, pro-inflammatory, and apoptosis markers in 
the liver, heart and kidneys versus iron sucrose originator.
conclusion: In our rat model, ferric carboxymaltose similar 
had a less favourable safety profile than iron sucrose originator, 
adversely affecting iron deposition, oxidative and nitrosative 
stress, inflammatory responses, with impaired liver and kidney 
function.
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Animals and treatments: Animal experiments were approved by 
the Hospital Alemán Ethic Committee and the Teaching and Research 
Committee and were undertaken according to the NIH Guide for the 
Care and Use of Laboratory Animals. Animals were housed, fed, 
and treated with IV iron compounds (40 mg iron/kg body weight) 
or control solution (equivalent volume) as described previously [11] 
Briefly, rats were randomised with equal male-female distribution to 
receive FCMS (Encicarb®, lot LHA11001, Emcure Pharmaceutical, 
Hinjwadi, India) n=8, IS {Venofer®, Vifor (International) Ltd., St. 
Gallen, Switzerland} n=8, or saline solution (control) injections n=8, 
on days 0, 7, 14, 21 and 28. The investigators were blinded to the 
treatments. Blood and urine samples were collected as described 
previously [16]. Rats were sacrificed 24 hour after the last IV injection 
(day 29) and the liver, heart and kidneys were removed for further 
analyses.
This study included four additional groups treated with various ISSs. 
The results of these groups have been published separately and, 
thus, the IS and control group data have already been described 
elsewhere [17].
Blood pressure: At baseline and 24 hour after each IV iron 
administration, Systolic Blood Pressure (SBP) and Diastolic Blood 
Pressure (DBP) were measured by a non-invasive pressure device 
using volume pressure recording, CODA 2 (Kent Scientific Co., 
Torrington, CT) as described previously [16].
Haemoglobin, serum iron and transferrin saturation: Hb 
concentration was determined by SYSMEX XT 1800i (Roche 
Diagnostic GmbH, Mannheim, Germany). Serum iron was 
assessed by colorimetric methods using an Autoanalyser Modular 
P800 with corresponding reagents (Roche Diagnostic GmbH, 
Mannheim, Germany). Serum transferrin was determined by radial 
immunodiffusion (Diffu-Plate, Biocientifica S.A., Buenos Aires, 
Argentina). Transferrin saturation (TSAT, %) was calculated with the 
following equation: serum iron concentration (µg/l)/total iron binding 
capacity (µg/l) ×100.
Liver enzymes and kidney parameters: Liver enzymes Aspartate 
Aminotransferase (AST), Alanine Aminotransferase (ALT), and 
Alkaline Phosphatase (ALP), were assessed in the blood samples 
by colorimetric and ultraviolet (UV) methods using an Autoanalyser 
Modular P800 (Roche Diagnostic GmbH, Mannheim, Germany). 
Aliquots of urine and sera were assessed for creatinine with the 
enzymatic UV method (Randox Laboratories Ltd., Crumlin, Northern 
Ireland) and standard formula was used to calculate creatinine 
clearance (CrCl). Sulfosalicylic acid method was used to detect 
proteinuria.
oxidative stress markers: Samples of the whole liver, heart and 
kidneys were homogenised in ice cold 0.25 M sucrose solution (1:3, 
w:v) for the determination of. glutathione (GSH), Cu, Zn superoxide 
dismutase (Cu, Zn-SOD) and glutathione peroxidase (GPx), and 
homogenised  in 0.05 M sodium phosphate buffer (pH 7.4; 1:10, 
w:v) for the determination of catalase as described previously 
[10,16].
Light microscopy, immunohistochemistry and morphometric 
analysis: Preparation of tissue samples, immunolabelling of 
specimen, and light microscopy were carried out as described 
previously [10,11,16]. Iron(III) deposits were quantified with Prussian 
blue staining. Ferritin was quantified with a goat polyclonal anti-
ferritin L antibody (sc-14420, Santa Cruz Biotechnology, Santa 
Cruz, CA, USA). Markers of inflammation, nitrosative stress and 
apoptosis were quantified with antibodies against tumour necrosis 
factor-alpha (TNF-α interleukin-6 (IL-6), nitrotyrosine and caspase 3. 
Histological sections were studied by an image analyser, Image-Pro 
Plus 4.5 for Windows (Media Cybernetics, LP Silver Spring, MD, 
USA). Morphological analyses were performed at magnifications of 
100, 400 or 1000 by two blinded, independent observers. Mean 
values of iron(III) deposits, tissue ferritin, TNF-α, IL-6, nitrotyrosine 
(percentage of area with positive staining/mm2) and caspase 3 
(number of cells with positive staining /mm2) were calculated for 
each rat.
stAtIstIcAL AnALysIs
All statistical analyses were performed as described previously 
[17]. Values are expressed as mean±SD and a p-value <0.05 was 
considered significant.
REsuLts
Molecular weight distribution of FcMs: The weight average 
molecular weight (Mw), number average molecular weight (Mn) and 
polydispersity (P) of the two FCMS lots (LHA11001/BVB13001) 
were 129/111 kDa, 95.6/85 kDa, and 1.35/1.31, respectively. The 
Mw, Mn and P of the two FCMORIG lots (073093/077585) were 
157/141 kDa, 94.7/89.5 kDa, and 1.66/1.57, respectively (see 
supplementary material S1).
Blood pressure measurements: A significant decrease (p<0.01) 
both in systolic (SBP) and diastolic blood pressure (DBP) was 
recorded in the FCMS group compared to the control and the IS 
throughout the study. The blood pressure values in the IS group 
were comparable to those of the control group [Table/Fig-1].
Liver and kidney function: AST, ALT and ALP were significantly 
increased (p<0.01) in the FCMS group compared to the IS and 
control groups throughout the study [Table/Fig-2]. Creatinine 
Clearance (CrCl) did not differ significantly between the groups on 
days 1, 8 and 15. On days 22 and 29, CrCl was significantly lower 
(p<0.01) in FCMS-treated animals than in IS-treated animals or in 
[table/Fig-1]: Systolic (SBP) and diastolic (DBP) blood pressures. Animals 
were treated weekly with 40 mg iron/kg body weight iron sucrose (IS) or ferric 
carboxymaltose similar (FCMS), or with saline solution (control). Data are shown as 
mean ± standard deviation (n = 8)
[table/Fig-2]: Body weight, blood iron parameters, liver enzymes and creatinine 
clearance (CrCl). Animals were treated weekly with 40 mg iron/kg body weight iron 
sucrose (IS) or ferric carboxymaltose similar (FCMS), or with saline solution (control). 
Data are shown as mean ± standard deviation (n = 8) (*p<0.01 vs control)
Control iS FCMS
Body weight (g)
Baseline 238.5 ± 29.5 240.1 ± 25.5 242.4  ± 27.0
Day 29 321.6 ± 30.4 316.8 ± 28.1 315.3 ± 29.9
Blood iron parameters (baseline)
Hb (g/dL) 15.7 ± 0.8 15.6 ± 0.9 15.7 ± 0.9
Serum iron (µg/dL) 295.7 ± 22.4 303.4 ± 21.6 298.5 ± 20.8
TSAT (%) 44.9 ± 3.8 44.7 ± 4.1 45.0 ± 3.9
Blood iron parameters (day 29)
Hb (g/dL) 15.8 ± 0.9 15.9 ± 0.8 15.8 ± 0.8
Serum iron (µg/dL) 299.0 ± 19.0 396.0 ± 32.0 509.0 ± 46.0*
TSAT (%) 45.1  ± 3.1 70.5 ± 3.3 87.7 ± 4.8*
Liver enzymes (day 29)
AST (UI/L) 118.9 ± 16.0 129.4 ± 13.0 205.5 ± 14.0*
ALT (UI/L) 55.8 ± 11.0 59.5 ± 7.1 90.9 ± 12.0*
ALP (UI/L) 519.8 ± 27.1 550 ± 23.0 728.6 ± 30.0*
crcl (ml/min)
Day 1 2.95 ± 0.11 2.84 ± 0.13 2.93 ± 0.17
Day 15 2.98 ± 0.14 2.76 ± 0.10 2.78 ± 0.20
Day 29 3.03 ± 0.12 2.89 ± 0.12 2.39 ± 0.18*
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the control group [Table/Fig-2]. IS treatment increased proteinuria 
only slightly during the study period, but FCMS treatment resulted 
in significantly higher (p<0.01) levels of proteinuria throughout the 
study [Table/Fig-3].
Iron parameters: As expected for non-anaemic rats, no significant 
differences were observed in the Hb concentrations between 
the control and IV iron-treated animals [Table/Fig-2]. Serum iron 
concentration and TSAT were significantly increased (p<0.01) in 
both IS- and FCMS-treated rats vs control. Both parameters were 
significantly higher (p<0.01) in FCMS- vs IS-treated rats [Table/
Fig-2].
A significantly larger (p<0.01) area for iron(III) deposits [Table/Fig-4a] 
and L-ferritin [Table/Fig-4b] was observed in both IV iron-treated 
groups vs the control group. In general, FCMS-treated animals 
showed significantly higher staining for iron(III) deposits than IS-
treated animals, whereas IS-treated animals showed significantly 
higher immunostaining for L-ferritin in all tissues compared to 
FCMS-treated animals. In the FCMS group, iron(III) deposits were 
located both in the Kupffer cells and hepatocytes, whereas in the IS 
group they were only present in the Kupffer cells [Table/Fig-4a]. In 
the heart, iron(III) deposits were found in the myocardium and in the 
kidney mainly in the cortex and in proximal tubular epithelial cells in 
both IV iron-treated groups [Table/Fig-4a].
oxidative stress markers: Lipid peroxidation was significantly 
increased (p<0.01) in all the tissues of FCMS-treated rats compared 
to the control and IS groups [Table/Fig-5a]. Activities of Cu, Zn-
SOD, catalase and GPx were also significantly increased in all the 
tissues of FCMS-treated animals compared to the control and IS 
groups [Table/Fig-6]. Furthermore, GSH:GSSG was significantly 
lower (p<0.01) in the FCMS group than in the control or IS groups 
[Table/Fig-6].
[table/Fig-6]: Oxidative stress markers in tissue homogenates on day 29. Animals 
were treated weekly with 40 mg iron/kg body weight iron sucrose (IS) or ferric 
carboxymaltose similar (FCMS), or with saline solution (control). Data are shown as 




Cu, Zn-SOD (U/mg prot) 5.0 ± 0.4 5.7 ± 0.7 10.6 ± 0.8*
Catalase (U/mg prot) 243.9 ± 21.0 258.2 ± 24.0 400.3 ± 30.9*
GPx (U/mg/prot) 258.7 ± 19.3 269.1 ± 21.0 383.5 ±17.1*
GSH:GSSG 7.9 ± 0.6 7.5 ± 0.5 3.8 ± 0.5*
Heart
Cu,Zn-SOD (U/mg prot) 10.3 ± 1.2 10.6 ± 1.1 15.9 ± 0.9*
Catalase (U/mg prot) 25.1 ± 4.7 28.7 ± 3.8 53.5 ± 3.6*
GPx (U/mg/prot) 139.9 ± 15.8 145.4 ± 19.0 227.7 ± 18.9*
GSH:GSSG 6.8 ± 0.3 6.4 ±0.4 3.7 ± 0.3*
Kidney
Cu,Zn-SOD (U/mg prot) 5.1 ± 0.7 5.3 ± 0.6 9.7 ± 0.8*
Catalase (U/mg prot) 137.6 ± 9.8 142.5 ± 7.9 187.2 ± 8.8*
GPx (U/mg/prot) 92.1 ± 8.2 98.4 ± 10.1 157.1 ± 10.8*
GSH:GSSG 7.9 ± 0.7 7.6 ± 0.5 4.4 ± 0.5*
[table/Fig-3]: Proteinuria. Animals were treated weekly with 40 mg iron/kg body 
weight iron sucrose (IS) or ferric carboxymaltose similar (FCMS), or with saline solution 
(control). Data are shown as mean ± standard deviation (n = 8)
[table/Fig-4]: Prussian blue (a) and ferritin (b) deposits on day 29. Animals 
were treated weekly with 40 mg iron/kg body weight iron sucrose (IS) or ferric 
carboxymaltose similar (FCMS), or with saline solution (control). Data are shown as 
mean ± standard deviation (n = 8)
[table/Fig-5]: Lipid peroxidation (a) and tyrosine nitration (b) on day 29. Animals 
were treated weekly with 40 mg iron/kg body weight iron sucrose (IS) or ferric 
carboxymaltose similar (FCMS), or with saline solution (control). Data are shown as 
mean ± standard deviation (n = 8)
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tyrosine nitration: FCMS-treated animals showed significantly 
higher (p<0.01) immunostaining for nitrotyrosine in the liver (Kupffer 
cells), heart (interstitium and cardiomyocytes) and kidneys (tubular 
epithelial cells) than animals treated with saline [Table/Fig-5b]. IS-
treated animals did not show any differences compared to the 
control group in any of the studied tissues.
Proinflammatory markers: Both proinflammatory markers TNF-α 
[Table/Fig-7a] and IL-6 [Table/Fig-7b] were significantly increased 
(p<0.01) in the liver, heart and kidneys of both IS- and FCMS-treated 
animals vs control group. However, the levels were significantly 
higher in the FCMS group than in the IS group.
Apoptosis: Immunostaining for caspase 3 was significantly 
increased (p<0.01) in FCMS-treated animals in the liver, heart and 
kidneys compared to the IS and control groups [Table/Fig-8].
dIscussIon
Polynuclear iron(III)-oxyhydroxide carbohydrate complexes for IV 
iron therapy cannot be fully characterised by physico-chemical 
analyses. Thus, regulatory authorities are considering the 
requirement of additional preclinical and/or clinical studies in order 
to show bioequivalence between an original and a copy [15,19]. 
The non-clinical model used in this study has allowed to identify 
significant differences in the potential of IS and ISSs to induce 
oxidative/nitrosative stress and inflammation [16,17] Moreover, 
the FCM originator (FCMORIG, Ferinject®) has shown effects 
comparable to those of IS in this model [10,11]. Thus, and due to 
the fact that IS has been tested numerous times in this model with 
highly reproducible results, IS was considered as internal standard 
[16-18].
In this study, administration of FCMS resulted in significantly higher 
levels of Transferrin Saturation (TSAT) and significantly higher 
Prussian blue-detectable iron(III) deposits in the analysed tissues 
than administration of IS. Moreover, levels of ferritin deposits in the 
FCMS group were much lower than in the IS group. Administration 
of FCMORIG has repeatedly resulted in TSAT values similar to 
those obtained with IS as well as in optimal tissue iron distribution 
indicated by increased ferritin levels in this rat model [10,11]. The 
unfavourable distribution of iron within the tissues of FCMS-treated 
rats suggests that iron from FCMS is able to bypass the regulated 
pathway through resident macrophages of the bone marrow, liver 
and spleen. The fact that administration of FCMS resulted in higher 
TSAT values may indicate the formation of larger amounts of non-
transferrin-bound iron (NTBI), which may be taken up uncontrolled 
by the liver, heart and kidneys tissues [3].
The levels of oxidative and nitrosative stress markers, TNF-α and 
IL-6, as well as caspase 3 levels were all higher in the FCMS group 
compared to the IS and control groups. In addition, a comparison 
between the FCMS group of this study and a FCMORIG group of a 
previous study [11,12] show also higher levels for these markers in the 
FCMS-treated animals. We have previously reported similar results 
for various ISSs vs IS and postulated that the combined actions of 
NO•, TNF-α, and IL-6 may have contributed to the low ferritin levels 
and, concomitantly, to increased accumulation of iron not stored in 
ferritin [16,17]. Iron-induced toxicity is often linked to its suboptimal 
distribution and accumulation to non-hematopoietic tissues. In non-
clinical iron overload models, iron has been shown to accumulate 
within lysosomes in hepatocytes [20], cardiomyocytes [21] and 
proximal tubular epithelial cells [22]. Lysosomal accumulation of iron 
may result in subsequent hydroxyl radical-mediated rupture of the 
lysosomal membrane and leakage of the lysosomal cargo into the 
cytoplasm, ensuing oxidative and nitrosative stress reactions as well 
as apoptosis [23]. Accordingly, it is not only the amount of labile iron 
that may lead to tissue toxicities, but also depends on the properties 
and metabolism of the administered IV iron preparation [3]. 
For NBCDs, the manufacturing process largely defines clinically-
relevant properties, such as metabolism and biodistribution. The 
differences in the chromatograms between the FCMS and the FCM 
lots suggest that the two products are not identical, raising doubt 
on their equivalence as demonstrated in this study. In addition, 
the significant differences among the two FCMS lots indicate a 
manufacturing process that is not standardised. In contrast, the two 
randomly chosen lots of FCMORIG presented with almost identical 
chromatograms indicating a highly consistent manufacturing 
process. Thus, it is conceivable that specific physico-chemical 
properties of the FCMS complex may lead to differential responses 
[table/Fig-7]: TNF-α (a) and IL-6 (b) on day 29. Animals were treated weekly with 40 
mg iron/kg body weight iron sucrose (IS) or ferric carboxymaltose similar (FCMS), or 
with saline solution (control). Data are shown as mean ± standard deviation (n = 8)
[table/Fig-8]: Caspase 3 on day 29. Animals were treated weekly with 40 mg iron/
kg body weight iron sucrose (IS) or ferric carboxymaltose similar (FCMS), or with 
saline solution (control). Data are shown as mean ± standard deviation (n = 8)
Jorge E. Toblli et al., Toxicity of Ferric Carboxymaltose Copy www.jcdr.net
Journal of Clinical and Diagnostic Research. 2015 Dec, Vol-9(12): FF08-FF1212
  ParTiCUlarS oF ConTribUTorS:
1. Laboratory of Experimental Medicine, Hospital Alemán, School of Medicine, University of Buenos Aires, Av. Pueyrredon 1640, (1118) Buenos Aires, Argentina.
2. Laboratory of Experimental Medicine, Hospital Alemán, School of Medicine, University of Buenos Aires, Av. Pueyrredon 1640, (1118) Buenos Aires, Argentina.
3. Laboratory of Experimental Medicine, Hospital Alemán, School of Medicine, University of Buenos Aires, Av. Pueyrredon 1640, (1118) Buenos Aires, Argentina.
naMe, aDDreSS, e-Mail iD oF THe CorreSPonDing aUTHor:
Dr. Jorge E. Toblli,  
Laboratory of Experimental Medicine, Hospital Alemán, School of Medicine, University of Buenos Aires, Av. 
Pueyrredon 1640, 1118 Buenos Aires, Argentina.
E-mail : jorgetoblli@fibertel.com.ar
FinanCial or oTHer CoMPeTing inTereSTS: As declared above
Date of Submission: apr 08, 2015
Date of Peer Review: Jun 08, 2015
 Date of Acceptance: oct 08, 2015
Date of Publishing: Dec 01, 2015
in the macrophages, affecting degradation, release of iron and, 
ultimately, iron distribution as previously seen with very stable 
dextran-based IV iron preparations [3]. However, with the current 
knowledge it is not possible to point out the properties that influence 
the way how IV iron complexes are metabolised and thus, the fate 
of released iron.
Although not a direct comparison, it is evident from our results that 
FCMS does not have the same biological properties as FCMORIG. 
Clinical studies have reported differences in the efficacy [24] and 
safety [25,26] between IS and ISSs. Notably, a recently published 
Case Report described a hypersensitivity reaction which occurred 
upon injection of a 1 g iron dose of FCMS [27]. Despite the fact that, 
as recently concluded by an assessment of the European Medicine 
Agency [28], all IV iron products can induce hypersensitivity 
reactions, the question remains whether the physico-chemical 
and biological differences between FCMS and FCMORIG could 
potentially have contributed to the hypersensitivity reaction following 
FCMS administration in the reported clinical case. Therefore, as 
suggested for other non-biological complex drugs [14], both pre-
clinical and clinical data are required to demonstrate that FCMS has 
an appropriate and acceptable safety and efficacy profile and that 
the benefits outweigh the risks.
LIMItAtIon
A potential limitation of the presented study could be the absence of 
an iron-deficient diet group. However, the design of the study was 
focused on detecting differences in toxicity rather than efficacy of 
the different iron preparations.
concLusIon
In conclusion, FCMS had a less favourable safety profile than 
iron sucrose originator, in our rat model, adversely affecting iron 
deposition, oxidative and nitrosative stress, inflammatory responses, 
with impaired liver and kidney function.
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